Clinical Trial Search

Primary: Change From Baseline in the Total Hours of Awake Time/Day Spent in the OFF State at Week 12 — 5.17; 5.33; 4.92; 4.83 hours

Primary: Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA) — 18.4; 9.0 Percentage of participants

Primary: Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA) — 20.3; 6.5 Percentage of subjects

Primary: Number of Participants With a Composite Endpoint of Stroke and Systemic Embolic Events (SEE) in Participants Who Were Administered DU-176b Compared With Placebo — 15; 44…

Primary: Progression-Free Survival (PFS), as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 10.6; 15.1 months — p=0.0224

Primary: Evaluate the Long-term Safety and Effectiveness of EN3267 — 64; 87; 116; 14 participants

Primary: Adverse Events and Adverse Drug Reactions, Etc. — 82; 92; 174; 60 Participants

Primary: Serum Trough Concentration (C-trough) of Golimumab — 0.50 micrograms per milliliter (mcg/mL)

Primary: Post-dose PC20 Concentration After Receiving Differing Doses of Test, Reference, or Placebo — 0.608; 3.779; 4.432; 3.928 log(mg/mL) — p=<0.0001

Primary: Number of Participants With Any Local and Systemic Treatment Emergent Adverse Events — 58; 52 Participants

Primary: Serum Sodium Levels at Baseline and During Treatment — 141.0; 140.0; 139.2; 140.3 mmol/L

Primary: Clinical Attachment Level at Baseline, 3 Months and 6 Months — 5.5; 5.29; 4.64; 4.73 mm

Primary: Overall Survival（OS） — 7.8; 7.1 Months — p=0.035

Primary: Average Change From Baseline (CFB) in Best Corrected Visual Acuity (BCVA) in the Study Eye — 1.4; 4.3 letters — p=0.0011

Primary: Overall Change From Baseline in Abdominal Score (Abdominal Bloating, Abdominal Discomfort, and Abdominal Pain) Throughout the Treatment Period — -1.182; -1.898 score on…